Niche CDMO Intellipharmaceutics specializes in research development and manufacture of novel and generic controlled release and targeted release oral solid dosage drugs with an emphasis on opioid abuse deterrence. This makes them a focused partner for firms seeking specialized formulation development and manufacturing services.

Analytical Lab Advantage The Toronto contract analytical services lab offers methods development validation transfer quality control testing stability testing and category 1 abuse deterrent studies, enabling end to end development and testing support for partners.

Strategic Partnerships Past licensing and supply deals such as the Mallinckrodt agreement indicate openness to strategic partnerships and potential licensing opportunities with larger pharma players.

Boutique Flexibility With a small team size and agile operations they can deliver fast cycle development and high touch project management for niche customers and early stage partners seeking specialized dosage forms.

Quality Driven Outsourcing In house analytical capabilities plus QA and stability testing make them a credible outsourcing partner for other manufacturers looking to outsource analytical work and regulatory ready testing.